[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639158":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"University of Modena and Reggio Emilia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"1",null,"subjects failing CAB\u002FRPV LAI switching to BIC\u002FFTC\u002FTAF per clinical practice",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Cristina Mussini, Full Professor, MD","CONTACT","+390594222466","cristina.mussini@unimore.it",[19],{"facility":20,"status":10,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"AOU Modena","Modena","MO","41124","Italy","IT",{"type":27,"coordinates":28},"Point",[29,30],10.92539,44.64783,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":16,"phoneExt":10,"email":17},"Cristina Mussini, MD",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Cristina Mussini","Full Professor, MD","100639158","retrospectiveprospective-pilot-study-to-evaluate-efficacy-and-safety-of-switching-to-bicftctaf-in-pwh-with-a-previous-virological-failure-under-cabrpv-lai-100639158",false,"NCT07620652","Retrospective\u002FProspective Pilot Study to Evaluate Efficacy and Safety of Switching to BIC\u002FFTC\u002FTAF in PWH With a Previous Virological Failure Under CAB\u002FRPV LAI","BICPREVIR","Inclusion Criteria:\n\n* PWH with age \\>18 years\n* PWH with a confirmed virological failure on CAB\u002FRPV LAI in the last three years\n* PWH without RAMs versus FTC and TAF","ALL","18 Years",{"count":49,"type":50},30,"ESTIMATED","OBSERVATIONAL","This study is a pilot, multi-center, observational retrospective-prospective study, with two different Parts, as follows:\n\n1. Part 1(retrospective and prospective part): to evaluate efficacy and safety of switching to BIC\u002FFTC\u002FTAF in People living with HIV (PWH) who previously failed CAB\u002FRPV LAI in the last three years and received in the last three years boosted PI since any INSTI mutations were detected on RNA and\u002For DNA through NGS at failure\n2. Part 2 (prospective part only): to evaluate efficacy and safety of switching directly to BIC\u002FFTC\u002FTAF in PWH who failed CAB\u002FRPV LAI without any RAMs on RNA and\u002For DNA through NGS considered of potential relevance for bictegravir\n\nInclusion Criteria:\n\n* PWH with age \\>18 years\n* PWH with a confirmed virological failure on CAB\u002FRPV LAI in the last three years\n* PWH without RAMs versus FTC and TAF\n\nStudy population: 30 subjects failing CAB\u002FRPV LAI will be included in the study",[54],"HIV Infection",[56,57,58],"HIV","Long acting ART","Therapeutic switch","NOT_YET_RECRUITING","2026-05-26",{"date":62,"type":63},"2026-06-02","ACTUAL",{"date":65,"type":50},"2026-07",{"date":67,"type":50},"2027-06-30",{"name":37,"class":6},1]